Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-01-29

FDA Approved: CARBAMAZEPINE — Supplemental Application (Chartwell RX, LLC)

View source ↗

Summary

FDA approved a supplemental application to permit Chartwell RX, LLC to market a generic carbamazepine product under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Carbamazepine (Carbamazepine)

Snippet

SUPPL AP for CARBAMAZEPINE (CARBAMAZEPINE)